Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 185

Sort by

Sort Order Select

Journal Articles

Limited-stage Mantle Cell Lymphoma: Real-world outcomes according to nodal vs. extranodal presentation

Sun-Hye Ko, Michael Crump, John Kuruvilla, David Hodgson, Danielle Rodin, Tomohiro Aoki, Sita Bhella, Robert Kridel, Vishal Kukreti, Nauman Malik, Abi Vijenthira, Chloe Yang, Anca Prica

Blood (2025) 146 (Supplement 1): 2769.

https://doi.org/10.1182/blood-2025-2769

Published: 2025

Journal Articles

Sensitive peripheral residual disease (PRD) detection using clonotypic mass spectrometry (EasyM) in patients with newly diagnosed multiple myeloma (NDMM)

Rintu Sharma, Esther Masih-Khan, Harjot Singh Vohra, Sita Bhella, Christine Chen, Chloe Yang, Guido Lancman, Keith Stewart, Vishal Kukreti, Vathany Kulasingam, Abir Khaled, Zac McDonald, Liqiang Yang, Arleigh McCurdy, Suzanne Trudel

Blood (2025) 146 (Supplement 1): 2250.

https://doi.org/10.1182/blood-2025-2250

Published: 2025

Journal Articles

Longitudinal assessments of simple frailty tools can help predict outcomes of patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy: A prospective pilot study at Princess Margaret Cancer Centre

Anca Prica, Antonette Pillainayagam, Manjula Maganti, Tiana Coley, Abi Vijenthira, Samantha Mayo, John Kuruvilla, Michael Crump, Sita Bhella, Robert Kridel, Vishal Kukreti, Chloe Yang, Shabbir Alibhai, Christine Chen

Blood (2025) 146 (Supplement 1): 4530.

https://doi.org/10.1182/blood-2025-4530

Published: 2025

Journal Articles

An open-label rollover study to assess the long-term safety of ixazomib

Sebastian Grosicki, Markus Hansson, Meletios Dimopoulos, Tadao Ishida, Vishal Kukreti, Dok Hyun Yoon, Wee-Joo Chng, Oliver Bechter, Xuejun Peng, Paul Richardson

Blood (2025) 146 (Supplement 1): 7547.

https://doi.org/10.1182/blood-2025-7547

Published: 2025

Journal Articles

Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy

Rintu Sharma, Pamella Paul, Harjot Singh Vohra, Eshetu Atenafu, John Kuruvilla, Michael Crump, Robert Kridel, Sita Bhella, Vishal Kukreti, Chloe Yang, Abi Vijenthira, Anca Prica, Christine Chen

Blood (2025) 146 (Supplement 1): 5505.

https://doi.org/10.1182/blood-2025-5505

Published: 2025

Journal Articles

Evaluating the implementation of an electronic patient-reported outcome system supporting self-management of treatment-related impairments among patients with lymphoma

Christian Lopez, Jennifer Jones, Anthony Reiman, Sarah Neil-Sztramko, Kristin Campbell, David Langelier, Jonathan Greenland, Jackie Bender, Gillian Strudwick, Vishal Kukreti

Blood (2025) 146 (Supplement 1): 2639.

https://doi.org/10.1182/blood-2025-2639

Published: 2025

Journal Articles

Outcomes and treatment strategies following CD20/CD3 bispecific antibody failure in non-Hodgkin's lymphoma: A retrospective single-center study

Sun-Hye Ko, Tomohiro Aoki, Robert Kridel, Vishal Kukreti, Anca Prica, Abi Vijenthira, Chloe Yang, Michael Crump, John Kuruvilla

Blood (2025) 146 (Supplement 1): 4550.

https://doi.org/10.1182/blood-2025-4550

Published: 2025

Journal Articles

Radiotherapy consolidation post-autologous stem cell transplant in Relapsed/Refractory aggressive non-Hodgkin lymphoma improves progression-free and overall survival in patients with partial but not complete metabolic response pre-transplant

Blood (2025) 146 (Supplement 1): 7188.

https://doi.org/10.1182/blood-2025-7188

Published: 2025

Journal Articles

Do chip mutations predict frailty and toxicity in transplant-eligible patients with multiple myeloma?

Steven Chun-Min Shih, Harjot Singh Vohra, Sahar Khan, Salman Basrai, Esther Masih-Khan, Anup Devasia, Donna Reece, Suzanne Trudel, Keith Stewart, Sita Bhella, Vishal Kukreti, Chloe Yang, Guido Lancman, Rodger Tiedemann, Anca Prica, Eugene Leung, Aaron Schimmer, Sagi Abelson, Christine Chen

Blood (2025) 146 (Supplement 1): 5773.

https://doi.org/10.1182/blood-2025-5773

Published: 2025

Journal Articles

ALACRITY: A phase 1b/2 study of AZD0120 (BCMA/CD19 CAR-T cell therapy) in participants with relapsed or refractory light chain amyloidosis (AL)

Suzanne Lentzsch, Heather Landau, Vishal Kukreti, Sandra Mazzoni, Richa Manwani, Amit Bhattacharyya, Akhilesh Chamediya, Ashutosh Wechalekar

Blood (2025) 146 (Supplement 1): 8236.

https://doi.org/10.1182/blood-2025-8236

Published: 2025

Journal Articles

Patients with Poor Functional Status at Intake Experience Early Failure of CAR T-Cell Therapy for Third Line Treatment of RR-LBCL

Sita D. Bhella, Katrina Hueniken, Rachel Aitken, Carmel Waldron, Michael Crump, John Kuruvilla, Anca Prica, Vishal Kukreti, Robert Kridel, Abi Vijenthira, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Christine I Chen

Blood (2024) 144 (Supplement 1): 7791.

https://doi.org/10.1182/blood-2024-210635

Published: 2024

Journal Articles

Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy

Chathuri Abeyakoon, Vanessa Murad, Ho-Young Yhim, Inna Gong, John Kuruvilla, Michael Crump, Anca Prica, Vishal Kukreti, Sita D. Bhella, Christine I Chen, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Ur Metser, Robert Kridel, Abi Vijenthira

Blood (2024) 144 (Supplement 1): 4469.

https://doi.org/10.1182/blood-2024-201150

Published: 2024

Journal Articles

Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin

Anup Joseph Devasia, Olsen Chan, Harjot Vohra, Esther Masih-Khan, Chloe Yang, Sita Bhella, Rodger E Tiedemann, Vishal Kukreti, Christine I Chen, Keith Stewart, Donna Reece, Suzanne Trudel, Guido Lancman

Blood (2024) 144 (Supplement 1): 3787.

https://doi.org/10.1182/blood-2024-209131

Published: 2024

Journal Articles

Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)

Donna E Reece, Giovanni Piza Rodriguez, Mariela A Pantoja, Eshetu G Atenafu, Darrell White, Irwindeep Sandhu, Julie Stakiw, Michael Sebag, Terrance Comeau, Kevin Song, Jean Roy, Martha L Louzada, Arleigh McCurdy, Vishal Kukreti, Suzanne Trudel, Anca Prica, Rodger E Tiedemann, Christine I Chen

Blood (2024) 144 (Supplement 1): 3376.

https://doi.org/10.1182/blood-2024-206247

Published: 2024

Journal Articles

Rate of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated with First-Line Bendamustine Rituximab and Rituximab Maintenance

Juan Rangel-Patiño, John Kuruvilla, Anca Prica, Robert Kridel, Sita D. Bhella, Vishal Kukreti, Jan Delabie, Abi Vijenthira, Manjula Maganti, Michael Crump

Blood (2024) 144 (Supplement 1): 2352.

https://doi.org/10.1182/blood-2024-210922

Published: 2024

Journal Articles

Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy

Chathuri Abeyakoon, Sita D. Bhella, Katrina Hueniken, Rachel Aitken, Carmel Waldron, Anca Prica, Vishal Kukreti, Robert Kridel, Abi Vijenthira, Christine I Chen, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Michael Crump, John Kuruvilla

Blood (2024) 144 (Supplement 1): 1695.

https://doi.org/10.1182/blood-2024-201189

Published: 2024

Journal Articles

A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada

Tiana Kordbacheh, Anca Prica, Kelvin KW Chan, Mahmood Aminilari, Zharmaine Ante, Ning Liu, Inna Y Gong, Sita Bhella, Michael Crump, Abi Vijenthira, John Kuruvilla, Robert Kridel, Christine I Chen, Vishal Kukreti, Chloe Yang, Nauman Malik, David Hodgson, Danielle Rodin

Blood (2024) 144 (Supplement 1): 5134.

https://doi.org/10.1182/blood-2024-206375

Published: 2024

Journal Articles

Handgrip Strength - Finetuning an Objective Measure of Frailty in Transplant-Eligible Patients with Multiple Myeloma

Steven Shih, Harjot Vohra, Anup Joseph Devasia, Sahar Khan, Eshetu Atenafu, Donna Reece, Suzanne Trudel, A. Keith Stewart, Sita D. Bhella, Vishal Kukreti, Chloe Yang, Rodger E. Tiedemann, Anca Prica, Eugene Leung, Christine I Chen

Blood (2024) 144 (Supplement 1): 4690.

https://doi.org/10.1182/blood-2024-198797

Published: 2024

Journal Articles

Diagnostic Test Accuracy of Fat Pad Sampling and Bone Marrow Biopsies in the Diagnosis of AL Amyloidosis: A Systematic Review and Meta-Analysis

Blood (2024) 144 (Supplement 1): 6896.

https://doi.org/10.1182/blood-2024-210641

Published: 2024

Journal Articles

Real World Outcomes in Adult Histiocytosis: 23-Year Canadian Single Center Analysis

Rintu Sharma, Alfredo H. De La Torre, Umberto Falcone, Eshetu G. Atenafu, Harjot Vohra, Jan Delabie, Michael Crump, Vishal Kukreti

Blood (2024) 144 (Supplement 1): 5388.

https://doi.org/10.1182/blood-2024-209411

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Limited-stage Mantle Cell Lymphoma: Real-world outcomes according to nodal vs. extranodal presentation

Sensitive peripheral residual disease (PRD) detection using clonotypic mass spectrometry (EasyM) in patients with newly diagnosed multiple myeloma (NDMM)

Longitudinal assessments of simple frailty tools can help predict outcomes of patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy: A prospective pilot study at Princess Margaret Cancer Centre

An open-label rollover study to assess the long-term safety of ixazomib

Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy

Evaluating the implementation of an electronic patient-reported outcome system supporting self-management of treatment-related impairments among patients with lymphoma

Outcomes and treatment strategies following CD20/CD3 bispecific antibody failure in non-Hodgkin's lymphoma: A retrospective single-center study

Radiotherapy consolidation post-autologous stem cell transplant in Relapsed/Refractory aggressive non-Hodgkin lymphoma improves progression-free and overall survival in patients with partial but not complete metabolic response pre-transplant

Do chip mutations predict frailty and toxicity in transplant-eligible patients with multiple myeloma?

ALACRITY: A phase 1b/2 study of AZD0120 (BCMA/CD19 CAR-T cell therapy) in participants with relapsed or refractory light chain amyloidosis (AL)

Patients with Poor Functional Status at Intake Experience Early Failure of CAR T-Cell Therapy for Third Line Treatment of RR-LBCL

Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy

Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin

Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)

Rate of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated with First-Line Bendamustine Rituximab and Rituximab Maintenance

Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy

A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada

Handgrip Strength - Finetuning an Objective Measure of Frailty in Transplant-Eligible Patients with Multiple Myeloma

Diagnostic Test Accuracy of Fat Pad Sampling and Bone Marrow Biopsies in the Diagnosis of AL Amyloidosis: A Systematic Review and Meta-Analysis

Real World Outcomes in Adult Histiocytosis: 23-Year Canadian Single Center Analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only